Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis

NCT04682639 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04682639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2020
Completion date
June 30, 2023
Enrollment
108 (actual)
Sites
256

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis